Inhibition of TNFR1 expression in HCC by using CAY10500 produced therapeutic effects as indicated by increasing the survival rate, reducing the serum AFP level, decreasing liver nodules, and improving hepatocytes’ structure. This evidence concerns the gene TNFRSF1A and hepatocellular carcinoma.